Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PDI-192 · 1 trial · 1 indication
Success rate, based on IGA score. Success rate is defined as the percentage of subjects who achieve "Clear" (score = 0) or "Almost Clear" (score = 1) and at least a 2-grade improvement from Baseline on the IGA score at Day 29. IGA is a measure of overall severity of atopic dermatitis using a 5-point ordinal scale from 0 = clear to 4 = severe.
| Arm | Type | Description |
|---|---|---|
| PDI-192 Foam, 0.1% | EXPERIMENTAL | topical foam, 0.1% concentration, twice daily |
| PDI-192 Foam, 0.15% | EXPERIMENTAL | topical foam, 0.15% concentration, twice daily |
| Vehicle Foam | PLACEBO_COMPARATOR | topical foam, 0% concentration, twice daily |
| Name | Type | Description |
|---|---|---|
| PDI-192 | DRUG | - |
| Vehicle | DRUG | - |
Inclusion Criteria: * Subject presents with a clinical diagnosis of stable mild to moderate atopic dermatitis. * Subject has used the same type of soap, moisturizers, lotions, creams, ointments, sunscreens or other skin products, and hair products (shampoo, etc.) for at least two weeks prior to stu...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
PDI-192 is an investigational small molecule being developed for the treatment of atopic dermatitis, a form of eczema. It is intended for use in patients with mild to moderate atopic dermatitis, as evaluated in a clinical trial that included participants as young as 3 months old.
PDI-192 is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol DTIL. The company is conducting clinical research on this investigational drug for atopic dermatitis.
PDI-192 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for treating atopic dermatitis.
PDI-192 has been studied in one completed Phase 2 clinical trial, identified as NCT01826461. This randomized, double-blind, placebo-controlled trial evaluated PDI-192 0.1% and 0.15% in the treatment of mild to moderate atopic dermatitis, enrolling 151 participants in the United States.
No alternative names for PDI-192 have been reported. It is identified solely by its code name PDI-192 in clinical trial records, and no other drug names or aliases are associated with this investigational compound.